icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
ZSgWTB39ypjb1Sd4
Listen
